Vaccine development against the Taenia solium parasite: the role of recombinant protein expression in Escherichia coli.
Bioengineered
; 4(5): 343-7, 2013.
Article
in En
| MEDLINE
| ID: mdl-23196744
ABSTRACT
Taenia solium is a zoonotic parasite that causes cysticercosis. The parasite is a major cause of human disease in impoverished communities where it is transmitted to humans from pigs which act as intermediate hosts. Vaccination of pigs to prevent transmission of T. solium to humans is an approach that has been investigated to control the disease. A recombinant vaccine antigen, TSOL18, has been remarkably successful at reducing infection of pigs with T. solium in several experimental challenge trials. The vaccine has been shown to eliminate transmission of naturally acquired T. solium in a field trial conducted in Africa. We recently reported that the vaccine was also effective in a field trial conducted in Peru. The TSOL18 recombinant antigen for each of these trials has been produced by expression in Escherichia coli. Here we discuss research that has been undertaken on the TSOL18 antigen and related antigens with a focus on improved methods of preparation of recombinant TSOL18 and optimized expression in Escherichia coli.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Cysticercosis
/
Vaccines, Synthetic
/
Taenia solium
/
Escherichia coli
/
Antigens, Helminth
Limits:
Animals
/
Humans
Language:
En
Journal:
Bioengineered
Year:
2013
Document type:
Article
Affiliation country:
Australia
Publication country:
EEUU
/
ESTADOS UNIDOS
/
ESTADOS UNIDOS DA AMERICA
/
EUA
/
UNITED STATES
/
UNITED STATES OF AMERICA
/
US
/
USA